MaxCyte (NASDAQ:MXCT) Stock Rating Upgraded by Wall Street Zen

MaxCyte (NASDAQ:MXCT) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of MaxCyte in a report on Monday, December 29th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, MaxCyte presently has an average rating of “Hold” and an average target price of $7.00.

MaxCyte Price Performance

Shares of NASDAQ:MXCT opened at $0.81 on Friday. MaxCyte has a 1 year low of $0.75 and a 1 year high of $4.49. The business’s 50-day moving average is $1.36 and its 200-day moving average is $1.53. The company has a market capitalization of $86.19 million, a price-to-earnings ratio of -1.84 and a beta of 1.21.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). The business had revenue of $6.41 million during the quarter, compared to analyst estimates of $8.37 million. MaxCyte had a negative net margin of 132.57% and a negative return on equity of 23.50%. Analysts anticipate that MaxCyte will post -0.42 EPS for the current year.

Hedge Funds Weigh In On MaxCyte

Large investors have recently added to or reduced their stakes in the business. Mirabella Financial Services LLP raised its holdings in shares of MaxCyte by 78.4% in the second quarter. Mirabella Financial Services LLP now owns 6,600,000 shares of the company’s stock valued at $14,388,000 after purchasing an additional 2,900,000 shares during the last quarter. May Hill Capital LLC bought a new stake in MaxCyte in the 2nd quarter worth about $27,000. Los Angeles Capital Management LLC purchased a new stake in MaxCyte in the 2nd quarter valued at about $138,000. Epacria Capital Partners LLC increased its stake in MaxCyte by 178.2% in the 2nd quarter. Epacria Capital Partners LLC now owns 62,133 shares of the company’s stock valued at $135,000 after buying an additional 39,796 shares during the last quarter. Finally, Willis Investment Counsel lifted its position in shares of MaxCyte by 126.8% during the 3rd quarter. Willis Investment Counsel now owns 862,758 shares of the company’s stock worth $1,363,000 after buying an additional 482,287 shares in the last quarter. Institutional investors own 68.81% of the company’s stock.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.